FDA Clears Pathwork's Tissue-of-Origin Cancer Test for Affy Platform | GenomeWeb
NEW YORK (GenomeWeb News) – The US Food and Drug Administration said today that it has cleared for marketing a microarray-based test from Pathwork Diagnostics that determines what type of cancer cells are present in a malignant tumor.
The Pathwork Tissue of Origin test is based on Pathwork’s PathChip gene-expression array, which runs on Affy’s GCS3000Dx diagnostic platform. The test considers 15 common malignant tumor types, including bladder, breast, and colorectal tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.